Restructuring gives embattled Orphazyme three paths to survival
Capital is crucial when operating a healthy business, and all signs point to Orphazyme’s wallet being empty. A lawyer with bankruptcy experience highlights three potential ways Orphazyme might keep its head above water, while an analyst says it all hinges on a single meeting.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen and catherine brett
Ever since Orphazyme’s hope to see drug candidate arimoclomol approved in the US was quashed in June of 2021, the company has been in a free fall in more ways than one. Today, the company’s share price also tells a story of its own.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme CEO stays silent in run-up to creditor meeting
For subscribers
Orphazyme gets another annual report extension approved
For subscribers
.jpg&w=384&q=75)
